AI Article Synopsis

Article Abstract

Expression of secretoglobin family 2A member 2 (SCGB2A2, also known as mammaglobin-1) has been detected in a high percentage of primary and metastatic breast tumors, to a lesser extent in normal breast, but not in other normal tissues. Plasmid transfection studies in our lab and others, however, were unable to identify the genetic elements regulating this specificity. Here we demonstrate that a 25-kb DNA fragment derived from the human SCGB2A2 gene upstream of the protein coding sequence was highly active and preferentially expressed in breast cancer cells when introduced via a helper-dependent adenoviral (HDAd) vector. HDAd delivery was selected for its high cloning capacity, its high efficiency of gene transfer, and the absence of cis-acting viral sequences that can potentially interfere with specificity of the inserted promoters. A series of vectors with deletions in the 25-kb fragment was constructed to identify important regulatory regions of the SCGB2A2 promoter. We have determined that elements controlling the specificity of expression reside within the first 345 bp upstream of the coding sequence. In addition, we identified a strong enhancer several kilobases upstream of this minimal promoter. We suggest that the SCGB2A2 promoter/enhancer should be particularly advantageous for gene therapy protocols involving oncolytic viruses or toxic gene transfer via adenovectors to mammary tumors.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ymthe.2004.06.849DOI Listing

Publication Analysis

Top Keywords

human scgb2a2
8
scgb2a2 mammaglobin-1
8
coding sequence
8
gene transfer
8
mammaglobin-1 promoter/enhancer
4
promoter/enhancer helper-dependent
4
helper-dependent adenovirus
4
adenovirus vector
4
vector directs
4
high
4

Similar Publications

Article Synopsis
  • A study in Mexico aimed to determine the detection rate of circulating tumor cells (CTCs) in Mexican women with early breast cancer using specific biomarkers KRT19, MUC1, and SCGB2A2.
  • The research involved 62 women, and blood samples were analyzed pre-surgery to quantify biomarker expression, confirming breast cancer in 59 cases.
  • Results showed that 32.2% of cases expressed at least one biomarker, with MUC1 detection rates similar to other populations but lower rates for KRT19 and SCGB2A2, highlighting the need for standardized methods in CTC detection.
View Article and Find Full Text PDF

Background: Breast cancer has the highest incidence rate of cancer worldwide, and brain metastases (BrM) are among the most malignant cases. While some patients have benefited from immune checkpoint inhibitors (ICIs), the complex anatomical structure of the brain and the heterogeneity of metastatic tumors have made it difficult to characterize the tumor immune microenvironment (TME) of metastatic tumors.

Methods: To address this, we used single-cell RNA sequencing (scRNA-seq) to analyze immune cells in the cerebrospinal fluid (CSF) of BrM patients with breast cancer, thereby providing a comprehensive view of the immune microenvironment landscape of BrM.

View Article and Find Full Text PDF

Human mammaglobin-A (SCGB2A2) is a secretory protein with an unknown function that is used as a diagnostic marker for breast cancer. However, other tumors can also express mammaglobin-A. To comprehensively study patterns of mammaglobin-A expression, a tissue microarray containing 16,328 samples from 128 different tumor types as well as 608 samples of 76 different normal tissue types was analyzed using immunohistochemistry.

View Article and Find Full Text PDF

Comparison of microfluidic platforms for the enrichment of circulating tumor cells in breast cancer patients.

Breast Cancer Res Treat

November 2022

Department of Obstetrics and Gynecology, Comprehensive Cancer Center, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.

Article Synopsis
  • The study investigates how to effectively isolate circulating tumor cells (CTCs) from blood using various microfluidic techniques to improve cancer diagnosis.
  • Blood samples from breast cancer patients were processed through different methods to enhance the recovery of CTCs while minimizing contamination from other blood cells.
  • Results showed that the method used significantly influenced the yield and purity of isolated tumor cells, with a notable disparity in the presence of cancer markers between early and metastatic breast cancer samples.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!